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Supplementary Figure 1 Full scan of blots in Fig. 1C. 
See the legend of Fig. 1C for details. 
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Supplementary Figure 2 Time courses of EGF-induced ERK phosphorylation. 
(a – c) The lysates from EGF-treated (50 or 0.3 ng ml–1) PC12 cells were subjected to Western 
blotting analysis with anti-phospho-ERK1/2 antibody at the indicated times.  
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Supplementary Figure 3 Time course and dose–response of exogenous GFP-ERK2.  
(a) Time course of EGF-induced (50 ng ml–1) phosphorylation of exogenous GFP-ERK2 and 
endogenous ERK2. (b, c) The levels of GFP-ERK2 phosphorylation (AU) were plotted as a 
function of EGF concentration with standard errors of three independent experiments. Hill 
coefficient was obtained by curve fitting with a Hill function.  
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Supplementary Figure 4 U0126 inhibits ERK phosphorylation and nuclear translocation. 
(a) PC12 cells were treated with 10 µM U0126 or DMSO for 30 min and subsequently 
stimulated with EGF (50 ng ml–1). The lysates were analysed by Western blotting with 
anti-phospho- ERK1/2 antibody. (b) U0126-treated PC12 cells stably expressing GFP-ERK2 
were stimulated with EGF (50 ng ml–1) and time-lapse images were obtained at a time 
resolution of 1 min. Scale bar, 10 µm. (c) Time courses of mean nuclear GFP-ERK2 intensities 
(fold change) in U0126-treated (410 cells) or non-treated cells (220 cells).  
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Supplementary Figure 5 EGF-induced nuclear translocation dynamics of GFP-ERK2.  
(a) Cells were stimulated with the indicated concentration of EGF and time-lapse images were 
obtained at a time resolution of 1 min. At least 180 cells were observed in each condition and 
data for single cells (y-axis) are shown in the figures. Nuclear intensities of GFP-ERK2 were 
normalised by the value before stimulation to obtain the fold change increase in nuclear ERK2 
concentration. (b) Averages of nuclear GFP-ERK2 intensities (fold change) in response to 
stimulation with the indicated concentrations of EGF.  
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Supplementary Figure 6 Mutual information of nuclear GFP-ERK2 and EGF concentration.  
In the context of input–output relation in cellular signalling, the mutual information indicates 
how many different input states are distinguishable according to a certain output value. From 
the symmetry of the formula, the mutual information also indicates how many output values can 
be adopted by the input. Here, the mutual information was approximately 1 bit (0.95 bits), 
suggesting that EGF induces two distinct modes of ERK nuclear translocation response. 
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Supplementary Figure 7 Time courses of NGF-induced ERK phosphorylation and nuclear 
translocation. 
(a) The lysates from NGF-treated (50 ng ml–1) PC12 cells were analysed by Western blotting 
with anti-phospho-ERK1/2 antibody at the indicated times, and shown with the time course 
induced by 50 ng ml–1 EGF (duplicated from Supplementary Fig. 2). (b) Averages of nuclear 
GFP-ERK2 intensities (fold change) in response to stimulation with the indicated 
concentrations of NGF.  
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Supplementary Figure 8 Confirmation of the specificity of anti-human ERK1 and anti-ERK2 
antibodies.  
The lysates from PC12 cells, PC12 cells stably expressing GFP-ERK2, and HeLa cells were 
subjected to Western blotting analysis with anti-human ERK1 antibody (left), anti-ERK1/2 
antibody (middle) and anti-ERK2 antibody (right). Note that no anti-human ERK1 signal was 
observed in the lysate from PC12 cells derived from rats. 
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Supplementary Figure 9 EGF-induced ERK response in HeLa cells. 
Serum-starved HeLa cells were stimulated with the indicated concentrations of EGF for 10 min, 
and triply immunostained with anti-human ERK1, anti-ERK2 and anti-phospho-ERK1/2 
antibodies. Scale bar, 10 µm.
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Supplementary Figure 10 Confirmation of ERK-mediated phosphorylation of Nup62 and 
Nup50 in digitonin-permeabilised cells.  
Mn2+-Phos-tag SDS-PAGE, followed by immunoblotting analyses of Nup62 and Nup50. 
Lysates were obtained as described in Fig. 4b. The asterisk indicates non-specific bands. 
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Supplementary Table 1 Rate equations of the model. 
Reaction Description 
 Input signal 
 Decay of signal 
 
ERK phosphorylation 
 ERK dephosphorylation in the cytoplasm 
 
Negative feedback to signal (Sos) 
 ERK nuclear import 
 ERK nuclear export 
 
ppERK nuclear import 
 
ppERK nuclear export 
 ERK dephosphorylation in the nucleus 
 
Nup phosphorylation 
 Nup dephosphorylation 
 Association of ppERK and substrate 
 Dissociation of ppERK–substrate complex 
 Substrate phosphorylation 
 Substrate dephosphorylation 
 
 12 
 
Supplementary Table 2 Equations and initial conditions. 
Species  Initial value
1      0   480,0002   96,0002   0   0   5,0003   0   96,0004   0   0 
1 Assuming that the cell volume was 1 pl1. 2 Total number of ERK molecules was assumed to be 
576,000 (~0.96 µM1). 3 Assumed based on the literature2,3. 4 Assumption (relatively determined 
by parameter fitting).  
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Supplementary Table 3 Parameter values. 
Parameter Value1 
 0.198 [ng ml
–1] 
 9.21e-2 
 5.90e-2 
 8.23e5 [c
 min-1] 
 9.30e2 
 1.01 
 2.03e-2 
 3.18e4 
 0.18
2 
 0.9
2 
 6.23e4 
 3.47e6 
 4.30e4 
 1.41e4 
 2.43e-02 [dimensionless] 
 3.55e1 
 1.95 [dimensionless] 
 2.46e3 
 1.60e1 
 1.12e-3 
 0.120 
 0.184 
 2.86e-6 
1 All units are shown in terms of number of molecules and minute except where otherwise 
explicitly indicated. c: arbitrary unit of concentration. 2 Assumed based on the literature4,5. 
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Supplementary Note 1 Kinetic modelling of ERK phosphorylation and nuclear translocation. 
The model is described in the following scheme.  
1) A transient input signal is induced in a stimulus-dependent manner and initiates the 
phosphorylation of cytoplasmic ERK. 
2) Cytoplasmic ppERK suppresses the input signals (negative feedback to Sos) 
3) ERK and ppERK undergo nucleocytoplasmic shuttling. 
4) Nup is phosphorylated by ppERK in proportion to the rate of nucleocytoplasmic shutting of 
ppERK. 
5) Nuclear ppERK binds nuclear substrates and catalyses phosphorylation. 
6) Phosphorylated ERK, Nup and substrates are dephosphorylated. 
The model did not explicitly include active transport for several reasons as follows. 1) ERK can 
enter the nucleus without transport carriers or energy6,7. 2) Active transport of ERK presumably 
requires dimerisation, but the rate of transport does not seem to be different between the 
wild-type and dimerisation-deficient mutant in living cells8. 3) The nuclear translocation model 
with active transport does not improve the fit to the data9.  
For the process of ERK-mediated phosphorylation of Nup, we assumed that ppERK both 
entering and exiting the nucleus is able to catalyse phosphorylation. Furthermore, the 
probability that Nup encounters ppERK is expected to be proportional to the amount of ppERK 
that passes through the nucleus per unit time rather than the concentration of cytoplasmic or 
nuclear ppERK. Therefore, in our model, the rate of Nup phosphorylation was proportional to 
the rate of ppERK translocation (See also Supplementary Table 1). 
At an early stage after stimulation, ERK is phosphorylated in the cytoplasm. Activated ERK 
passes across the nuclear envelope with phosphorylation of Nups and interacts with nuclear 
substrates, resulting in accumulation of ERK in the nucleus. ERK-mediated phosphorylation of 
Nups enhances ERK import, which works as positive feedback on nuclear import. On the other 
hand, the nuclear accumulation of ERK does not last long because the available substrates 
would be decreased by phosphorylation9, which functions as negative feedback for ERK nuclear 
 15 
import. Therefore, both positive and negative feedback regulations temporarily emerge. Indeed, 
positive and negative feedback is a motif observed in excitable systems that is known to 
inherently generate ultrasensitive responses10,11. Therefore, our ERK model could be interpreted 
as a modified form of the excitable system. 
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